2015 Q2 Form 10-Q Financial Statement

#000156459015004860 Filed on June 04, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q2
Revenue $89.92M $87.01M $66.72M
YoY Change 34.77% 38.55% 55.93%
Cost Of Revenue $31.99M $31.16M $25.95M
YoY Change 23.26% 27.91% 46.54%
Gross Profit $57.94M $55.86M $40.77M
YoY Change 42.11% 45.29% 62.57%
Gross Profit Margin 64.43% 64.19% 61.11%
Selling, General & Admin $24.06M $23.43M $19.22M
YoY Change 25.15% 21.54% 68.93%
% of Gross Profit 41.52% 41.95% 47.15%
Research & Development $12.96M $11.74M $8.992M
YoY Change 44.09% 49.43% 62.69%
% of Gross Profit 22.36% 21.02% 22.05%
Depreciation & Amortization $400.0K $1.000M $300.0K
YoY Change 33.33% 25.0% 50.0%
% of Gross Profit 0.69% 1.79% 0.74%
Operating Expenses $37.01M $35.17M $28.21M
YoY Change 31.19% 29.61% 66.89%
Operating Profit $20.93M $20.68M $12.56M
YoY Change 66.64% 82.91% 53.64%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $763.0K -$1.660M -$30.00K
YoY Change -2643.33% 354.79% -93.99%
Pretax Income $21.69M $19.02M $12.53M
YoY Change 73.13% 73.84% 63.24%
Income Tax $8.706M $5.697M $5.306M
% Of Pretax Income 40.14% 29.95% 42.36%
Net Earnings $12.98M $13.33M $7.221M
YoY Change 79.78% 113.32% 49.04%
Net Earnings / Revenue 14.44% 15.32% 10.82%
Basic Earnings Per Share $0.10 $0.10 $0.06
Diluted Earnings Per Share $0.09 $0.09 $0.05
COMMON SHARES
Basic Shares Outstanding 131.2M 130.3M 123.9M
Diluted Shares Outstanding 144.7M 144.7M 142.8M

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $428.5M $397.9M $345.5M
YoY Change 24.02% 38.11% 483.61%
Cash & Equivalents $107.6M $129.3M $188.9M
Short-Term Investments $320.9M $268.6M $156.6M
Other Short-Term Assets $6.235M $6.488M $5.500M
YoY Change 13.36% 27.42% 96.43%
Inventory
Prepaid Expenses
Receivables $70.20M $92.70M $61.22M
Other Receivables $0.00 $0.00 $4.500M
Total Short-Term Assets $509.8M $501.8M $418.8M
YoY Change 21.73% 41.87% 319.2%
LONG-TERM ASSETS
Property, Plant & Equipment $35.20M $28.20M $2.494M
YoY Change 1311.39% 1053.5% 66.27%
Goodwill $4.850M $4.850M
YoY Change 0.0% 0.0%
Intangibles $4.904M
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.800M $3.900M $1.212M
YoY Change 213.53% 240.61% 1.0%
Total Long-Term Assets $58.90M $43.06M $16.34M
YoY Change 260.42% 159.79% 366.91%
TOTAL ASSETS
Total Short-Term Assets $509.8M $501.8M $418.8M
Total Long-Term Assets $58.90M $43.06M $16.34M
Total Assets $568.7M $544.9M $435.1M
YoY Change 30.7% 47.15% 320.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.300M $3.900M $3.098M
YoY Change 71.08% 84.22% 82.24%
Accrued Expenses $14.80M $8.939M $7.876M
YoY Change 87.91% 12.71% -35.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $137.1M $135.5M $101.2M
YoY Change 35.43% 56.44% 63.8%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.600M $2.534M $1.909M
YoY Change 36.2% 33.58% 59.08%
Total Long-Term Liabilities $2.600M $2.534M $1.909M
YoY Change 36.2% 33.58% 59.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $137.1M $135.5M $101.2M
Total Long-Term Liabilities $2.600M $2.534M $1.909M
Total Liabilities $139.7M $138.1M $104.8M
YoY Change 33.25% 53.04% 65.36%
SHAREHOLDERS EQUITY
Retained Earnings $88.93M $55.76M
YoY Change 83.19%
Common Stock $317.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $429.0M $406.8M $330.3M
YoY Change
Total Liabilities & Shareholders Equity $568.7M $544.9M $435.1M
YoY Change 30.7% 47.15% 320.82%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q2
OPERATING ACTIVITIES
Net Income $12.98M $13.33M $7.221M
YoY Change 79.78% 113.32% 49.04%
Depreciation, Depletion And Amortization $400.0K $1.000M $300.0K
YoY Change 33.33% 25.0% 50.0%
Cash From Operating Activities $41.80M -$1.400M $18.10M
YoY Change 130.94% -108.59% 39.23%
INVESTING ACTIVITIES
Capital Expenditures $4.710M -$500.0K $299.0K
YoY Change 1475.25% 25.0% 37.79%
Acquisitions $9.987M
YoY Change
Other Investing Activities -$63.10M -$8.700M -$131.3M
YoY Change -51.94% -8.42% 21783.33%
Cash From Investing Activities -$67.80M -$9.200M -$131.8M
YoY Change -48.56% -7.07% 16375.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.300M 7.800M 40.10M
YoY Change -89.28% -880.0% 13266.67%
NET CHANGE
Cash From Operating Activities 41.80M -1.400M 18.10M
Cash From Investing Activities -67.80M -9.200M -131.8M
Cash From Financing Activities 4.300M 7.800M 40.10M
Net Change In Cash -21.70M -2.800M -73.60M
YoY Change -70.52% -151.85% -688.8%
FREE CASH FLOW
Cash From Operating Activities $41.80M -$1.400M $18.10M
Capital Expenditures $4.710M -$500.0K $299.0K
Free Cash Flow $37.09M -$900.0K $17.80M
YoY Change 108.36% -105.39% 39.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 us-gaap Other Assets Current
OtherAssetsCurrent
6235000
CY2015Q1 us-gaap Other Assets Current
OtherAssetsCurrent
6488000
CY2014Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
930000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
28214000
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
142849000
CY2014Q2 us-gaap Revenues
Revenues
66721000
CY2014Q2 us-gaap Cost Of Goods Sold Subscription
CostOfGoodsSoldSubscription
12040000
CY2014Q2 us-gaap Technology Services Costs
TechnologyServicesCosts
13910000
CY2014Q2 us-gaap Cost Of Revenue
CostOfRevenue
25950000
CY2014Q2 us-gaap Gross Profit
GrossProfit
40771000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8992000
CY2014Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12814000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6408000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
12557000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-30000
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5306000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
7221000
CY2014Q2 veev Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
7128000
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
123902000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
46000
CY2014Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-34000
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7233000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8560000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
37013000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
20925000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
763000
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8706000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
12982000
CY2015Q2 veev Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
12964000
CY2015Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
15496000
CY2015Q2 us-gaap Revenues
Revenues
89923000
CY2015Q2 us-gaap Technology Services Revenue
TechnologyServicesRevenue
21029000
CY2015Q2 us-gaap Cost Of Goods Sold Subscription
CostOfGoodsSoldSubscription
15873000
CY2015Q2 us-gaap Technology Services Costs
TechnologyServicesCosts
16112000
CY2015Q2 us-gaap Cost Of Revenue
CostOfRevenue
31985000
CY2015Q2 us-gaap Gross Profit
GrossProfit
57938000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12957000
CY2015Q2 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-763000
CY2014Q2 us-gaap Payments For Software
PaymentsForSoftware
220000
CY2014Q2 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
3000
CY2014Q2 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-131771000
CY2015Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1162000
CY2014Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
685000
CY2015Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2642000
CY2014Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3918000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
21688000
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
12527000
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131163000
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
144734000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2015Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-8000
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
12971000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4799000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3256000
CY2015Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1024000
CY2015Q2 us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
-7000
CY2014Q2 us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
28000
CY2015Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-23536000
CY2014Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2812000
CY2015Q2 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
2862000
CY2014Q2 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-2678000
CY2015Q2 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-33000
CY2014Q2 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1861000
CY2015Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-760000
CY2014Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
912000
CY2015Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1336000
CY2014Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5318000
CY2015Q2 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2197000
CY2014Q2 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
7492000
CY2015Q2 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
92000
CY2014Q2 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
12000
CY2015Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
41791000
CY2014Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
18130000
CY2015Q2 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
100837000
CY2014Q2 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
135116000
CY2015Q2 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
47744000
CY2014Q2 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
3867000
CY2015Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4710000
CY2014Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
299000
CY2015Q2 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
9987000
CY2015Q2 us-gaap Payments For Software
PaymentsForSoftware
22000
CY2015Q2 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-1000
CY2015Q2 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-67811000
CY2015Q2 veev Proceeds From Stock Options Early Exercised
ProceedsFromStockOptionsEarlyExercised
8000
CY2014Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
34994000
CY2015Q2 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4000
CY2015Q2 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
3169000
CY2014Q2 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
4379000
CY2015Q2 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4335000
CY2014Q2 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
40058000
CY2015Q2 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-7000
CY2014Q2 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-36000
CY2015Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-21692000
CY2014Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-73619000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
262507000
CY2014Q2 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-312000
CY2014Q2 veev Initial Public Offering Costs Incurred But Not Yet Paid
InitialPublicOfferingCostsIncurredButNotYetPaid
515000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188888000
CY2015Q2 veev Increase Decrease In Capital Expenditures Incurred But Not Yet Paid
IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid
2482000
CY2014Q2 veev Increase Decrease In Capital Expenditures Incurred But Not Yet Paid
IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid
69000
CY2015Q2 veev Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
17000
CY2014Q2 veev Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
119000
CY2015Q2 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect the condensed consolidated financial statements and the notes thereto. These estimates are based on information available as of the date of the condensed consolidated financial statements. On a regular basis, management evaluates these estimates and assumptions. Significant items subject to such estimates and assumptions include, but are not limited to: </p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:'Wingdings 2';font-size:10pt;">&#151;</p></td> <td valign="top" style="width:96.67%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the best estimate of selling price of the deliverables included in multiple-deliverable revenue arrangements; </p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;;font-family:'Wingdings 2';font-size:10pt;">&#151;</p></td> <td valign="top" style="width:96.67%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the collectibility of our accounts receivable;</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;;font-family:'Wingdings 2';font-size:10pt;">&#151;</p></td> <td valign="top" style="width:96.67%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the fair value of assets acquired and liabilities assumed for business combinations;</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;;font-family:'Wingdings 2';font-size:10pt;">&#151;</p></td> <td valign="top" style="width:96.67%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the valuation of short-term investments and the determination of other-than-temporary impairments;</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;;font-family:'Wingdings 2';font-size:10pt;">&#151;</p></td> <td valign="top" style="width:96.67%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the valuation of building and land;</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;;font-family:'Wingdings 2';font-size:10pt;">&#151;</p></td> <td valign="top" style="width:96.67%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the realizability of deferred income tax assets; </p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:'Wingdings 2';font-size:10pt;">&#151;</p></td> <td valign="top" style="width:96.67%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the fair value of our stock-based awards and related forfeiture rates; and </p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:94.27%;margin-left:5.73%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:'Wingdings 2';font-size:10pt;">&#151;</p></td> <td valign="top" style="width:96.67%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the capitalization and estimated useful life of internal-use software development costs. </p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As future events cannot be determined with precision, actual results could differ significantly from those estimates. </p></div>
CY2015Q2 us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Revenue </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Deferred revenue includes amounts billed to customers for which the revenue recognition criteria have not been met. The majority of deferred revenue primarily consists of billings or payments received in advance of revenue recognition from our subscription services described above and is recognized as the revenue recognition criteria are met. We generally invoice our customers in annual, quarterly or monthly installments for the subscription services, which are typically contracted for a term of one year or less. Accordingly, the deferred revenue balance does not generally represent the total contract value of a subscription arrangement. Deferred revenue that will be recognized during the succeeding 12-month period is recorded as current deferred revenue.</p></div>
CY2015Q2 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certain Risks and Concentrations of Credit Risk </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Our revenues are derived from subscription services, professional services and other services delivered primarily to the pharmaceutical and life sciences industry. We operate in markets that are highly competitive and rapidly changing. Significant technological changes, shifting customer needs, the emergence of competitive products or services with new capabilities and other factors could negatively impact our operating results. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and trade accounts receivable. Our cash equivalents and short-term investments are held in safekeeping by large, credit-worthy financial institutions. We have established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in these financial institutions may exceed federally insured limits. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not require collateral from our customers and generally require payment within 30 to 60 days of billing. We periodically evaluate the collectibility of our accounts receivable and provide an allowance for doubtful accounts as necessary, based on historical experience. Historically, such losses have not been material. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No single customer represented over 10% of accounts receivable in the condensed consolidated financial statements as of April 30, 2015 or January 31, 2015. No single customer represented over 10% of total revenues in the condensed consolidated financial statements for the three months ended April 30, 2015 and 2014.</p></div>
CY2015Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2670000
CY2015Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000
CY2014Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000
CY2015Q2 us-gaap Business Acquisition Effective Date Of Acquisition1
BusinessAcquisitionEffectiveDateOfAcquisition1
2015-03-31
CY2015Q1 veev Business Acquisition Cash Consideration
BusinessAcquisitionCashConsideration
10000000
CY2015Q1 veev Percentage Of Consideration To Be Held In Escrow Of Net Fair Value Of Acquisition
PercentageOfConsiderationToBeHeldInEscrowOfNetFairValueOfAcquisition
0.15
CY2015Q1 veev Period Of Closing Consideration Placement In Escrow
PeriodOfClosingConsiderationPlacementInEscrow
P12M
CY2015Q2 veev Business Acquisition Contingent Consideration Cash Payment
BusinessAcquisitionContingentConsiderationCashPayment
0
CY2015Q2 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
300000
CY2015Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
320857000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
126000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
36000
CY2015Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
268528000
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
118000
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
26000
CY2015Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
250106000
CY2015Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
224263000
CY2015Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
70841000
CY2015Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
44357000
CY2015Q2 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2015 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37679000
CY2015Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
30542000
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2506000
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2339000
CY2015Q2 us-gaap Depreciation
Depreciation
400000
CY2014Q2 us-gaap Depreciation
Depreciation
300000
CY2015Q2 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
3331000
CY2015Q1 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
3307000
CY2015Q2 us-gaap Capitalized Computer Software Accumulated Amortization
CapitalizedComputerSoftwareAccumulatedAmortization
2256000
CY2015Q1 us-gaap Capitalized Computer Software Accumulated Amortization
CapitalizedComputerSoftwareAccumulatedAmortization
2067000
CY2014Q2 us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
300000
CY2015Q2 us-gaap Capitalized Computer Software Amortization
CapitalizedComputerSoftwareAmortization
200000
CY2014Q2 us-gaap Capitalized Computer Software Amortization
CapitalizedComputerSoftwareAmortization
200000
CY2015Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
10874000
CY2015Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3084000
CY2015Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7574000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1826000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2282000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1854000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1154000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
596000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
78000
CY2015Q2 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
6225000
CY2015Q2 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
887000
CY2015Q1 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
1309000
CY2015Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1593000
CY2015Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1901000
CY2015Q2 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
3867000
CY2015Q1 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
3287000
CY2015Q2 veev Accrued Fees Current
AccruedFeesCurrent
3651000
CY2015Q1 veev Accrued Fees Current
AccruedFeesCurrent
3395000
CY2015Q2 veev Early Exercise Of Stock Options Liability
EarlyExerciseOfStockOptionsLiability
77000
CY2015Q1 veev Early Exercise Of Stock Options Liability
EarlyExerciseOfStockOptionsLiability
87000
CY2015Q2 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
925000
CY2015Q1 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
1666000
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3756000
CY2015Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3791000
CY2015Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.40
CY2014Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.42
CY2015Q2 veev Increase Decrease In Effective Income Tax Rate Continuing Operations
IncreaseDecreaseInEffectiveIncomeTaxRateContinuingOperations
0.02
CY2015Q2 veev Share Based Compensation Arrangement By Share Based Payment Award Shares Subject To Repurchase Liability Recorded
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesSubjectToRepurchaseLiabilityRecorded
100000
CY2015Q1 veev Share Based Compensation Arrangement By Share Based Payment Award Shares Subject To Repurchase Liability Recorded
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesSubjectToRepurchaseLiabilityRecorded
100000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20233620
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20800
CY2015Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
508216
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
68085
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19678119
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4114265
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
18637618
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.18
CY2015Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
24.49
CY2015Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.30
CY2015Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.31
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.25
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.71
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.23
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y6M
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
498862568
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
13003851
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
441306853
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
98616555
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
418360021
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.25
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.47
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
32800000
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
643638
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
600920

Files In Submission

Name View Source Status
0001564590-15-004860-index-headers.html Edgar Link pending
0001564590-15-004860-index.html Edgar Link pending
0001564590-15-004860.txt Edgar Link pending
0001564590-15-004860-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
veev-10q_20150430.htm Edgar Link pending
veev-20150430.xml Edgar Link completed
veev-20150430.xsd Edgar Link pending
veev-20150430_cal.xml Edgar Link unprocessable
veev-20150430_def.xml Edgar Link unprocessable
veev-20150430_lab.xml Edgar Link unprocessable
veev-20150430_pre.xml Edgar Link unprocessable
veev-ex101_20150430401.htm Edgar Link pending
veev-ex311_201504308.htm Edgar Link pending
veev-ex312_201504309.htm Edgar Link pending
veev-ex321_201504307.htm Edgar Link pending
veev-ex322_201504306.htm Edgar Link pending